SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Howe who wrote (3673)9/7/1999 12:37:00 PM
From: Biomaven  Read Replies (1) of 10280
 
Dave,

SEPR will receive at least $40 million per year once the US royalties start to roll in.

That's higher than the company seems to be projecting, which may mean that the US royalties are lower than people have been projecting.

One overall comment on your numbers is the issue of competition from generics. A good example are the proton pump blockers like Prevacid - it's not clear to me that the advantages of the ICE's in this area will be enough to provide substantial pricing premium over the generics.

Peter

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News